Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) is a global provider of products and services for individuals with chronic kidney failure. The company designs, manufactures and distributes a comprehensive range of dialysis machines, dialyzers and related disposables, as well as water treatment systems and monitoring equipment. In addition to its core product portfolio, Fresenius Medical Care offers clinical services through a network of outpatient dialysis centers, delivering both in-center and home-based hemodialysis and peritoneal dialysis treatments.
Beyond its clinical operations, the company maintains an extensive research and development program focused on advancing therapies for renal and associated cardiovascular complications. Its activities include innovations in biocompatible membranes, online hemodiafiltration and digital health solutions aimed at improving patient outcomes and operational efficiency. Support services range from patient education and nutritional counseling to laboratory testing and telemedicine platforms that facilitate remote monitoring and care coordination.
Fresenius Medical Care serves patients in more than 40 countries across Europe, North America, Asia-Pacific, Latin America and the Middle East & Africa. Its geographic footprint is supported by manufacturing facilities, logistics hubs and R&D centers strategically located to meet regional regulatory requirements and local market needs. Through partnerships with hospitals, healthcare providers and payers, the company seeks to expand access to renal care in both mature and emerging markets.
Established in 1996 through the merger of established renal care businesses, Fresenius Medical Care has grown into the largest integrated kidney care company worldwide. Headquartered in Bad Homburg, Germany, it operates under German corporate governance with a Management Board and a Supervisory Board. The executive team is responsible for setting strategic priorities around patient-centric innovation, quality standards and sustainable growth, reflecting the company’s commitment to advancing renal care globally.
